-->

Ivermectin in COVID-19

Ivermectin in COVID-19

Discover the truth about ivermectin in this enlightening documentary. Director Adrian Ursu travels back in time to share the facts about its natural origins and how it garnered a Nobel Prize in medicine.

Summary of studies on the use of ivermectin in COVID-19:

Source: Database of all ivermectin COVID-19 studies – www.c19ivermectin.com – (constantly updated)

 

Source: Global ivermectin adoption for COVID-19 – ivmstatus.com (constantly updated)

We regard ivermectin as a core medication in the prevention and treatment of COVID-19, and these pages contain the scientific rationale for our recommendation of the use of ivermectin in COVID-19. For comprehensive information on ivermectin please refer to our Review of the Emerging Evidence Supporting the Use of Ivermectin in the Prophylaxis and Treatment of COVID-19 and the included references.

The Safety of Ivermectin – High Doses

Many have questions about the safety of higher doses of this medicine for treatment after exposure or in-hospital critical care circumstances.   See our Ivermectin Safety Overview.

Ivermectin, neurotoxicity and p-glycoprotein
A brief summary of ivermectin and neurological side effects.

A recent paper, Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines was published online June 17, 2021, by the American Journal of Therapeutics. It concludes, “Moderate-certainty evidence finds that large reductions in COVID-19 deaths are possible using ivermectin. Using ivermectin early in the clinical course may reduce numbers progressing to severe disease. The apparent safety and low cost suggest that ivermectin is likely to have a significant impact on the SARS-CoV-2 pandemic globally.”

For PATIENTS AND RELATIVES, please review our GUIDE FOR YOU. It explains how to find physicians who will consider prescribing ivermectin and other medications in the FLCCC protocol, as well as provides information to share with your primary care physician in the event that he or she is not aware of the current evidence detailing how safe and effective ivermectin is in preventing and treating all stages of COVID-19 and all variants of the SARS-CoV-2 virus.

Ivermectin is a well-known, FDA-approved anti-parasite drug that has been used successfully for more than four decades to treat onchocerciasis “river blindness” and other parasitic diseases. It is one of the safest drugs known. It is on the WHO’s list of essential medicines, has been given over 3.7 billion times around the globe, and has won the Nobel prize for its global and historic impacts in eradicating endemic parasitic infections in many parts of the world.

A growing published medical evidence base demonstrates ivermectin’s unique and highly potent ability to inhibit SARS-CoV-2 replication and to suppress inflammation. Based on this evidence, and on first-hand clinical observations, our team recommends its use for prevention and treatment in all stages of COVID-19. View our protocols for more information on specific strategies.

Studies and clinical trials on ivermectin

Dec 29, 2021
“Global Use of Ivermectin”
An overview of the global use and effectiveness of ivermectin for the prevention and treatment of COVID-19.
Global Health Ministry Programs.

Aug 26, 2021
“Ivermectin as a SARS-CoV-2 Pre-Exposure Preventive in Healthcare Workers: a Propensity Score-Matched Retrospective Cohort Study”
a study from doctors who continued to use ivermectin to subdue COVID-19 with great success in the Dominican Republic.
IVM as a Covid Pre-Exposure Preventive.

Jun 15, 2021
“The mechanisms of action” of Ivermectin against SARS-CoV-2: An evidence-based clinical review article.” reports overwhelmingly positive data for ivermectin’s use in the pandemic.
“100% of 36 early treatment and prophylaxis studies report positive effects… using the most serious outcome reported 79% and 85% improvement for early treatment and prophylaxis respectively…Statistically significant improvements were seen for mortality, ventilation, hospitalization, cases, and viral clearance…100% of the 17 Randomized Controlled Trials (RCTs) for early treatment and prophylaxis report positive effects, with an estimated improvement of 73% and 83% respectively, and 93% of all 28 RCTs.)… The consistency of positive results across a wide variety of cases has been remarkable. It is extremely unlikely that the observed results could have occurred by chance.”

Favorable outcome on viral load and culture viability using Ivermectin in early treatment of non-hospitalized patients with mild COVID-19 – A double-blind, randomized placebo-controlled trial can be found here.

For an up-to-date overview of all published studies on ivermectin in the treatment and prevention of COVID-19 we recommend visiting c19ivermectin.com; in addition, a meta-analysis of all studies can be found at ivmmeta.com (constantly updated).

A majority of the studies (until January 12, 2021) were included in our comprehensive Review of the Emerging Evidence Supporting the Use of Ivermectin in the Prophylaxis and Treatment of COVID-19, and a brief summary of the studies at that time can be found in the accompanying One-page summary of the scientific review on ivermectin.

Update: The FLCCC Alliance’s “Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19” has been peer-reviewed, accepted, and published on May 1, 2021, in the American Journal of Therapeutics!

Further information

FLCCC Alliance review on ivermectin in COVID-19